WRAL Tech Wire

Pozen migraine drug licensed to Desitin for commercialization in Europe

The migraine headache treatment developed by Pozen now has a partner for commercialization in Europe.

Pozen losses increase but arthritis drug royalties grow

The Chapel Hill-based drug firm reports a loss of $8.4 million for the first quarter, up from $5.7 million a year ago. However, sales of the arthirtis drug Vimovo are growing.

Pozen runs into a headache with FDA over safer aspirin

During a recent meeting with the FDA to discuss its submission, the agency suggested the Chapel Hill-based company also seek approval for the drug at a lower dose

Pozen shares surge on aspirin therapy trial news

The Chapel Hill-based pharmaceutical firm says its compound redcues gastric ulcers in two Phase 3 trials of patients who are taking aspirin daily. Pozen plans a new drug application in the third quarter. PLUS: Two board memebers leaving.

Diagram from Pozen presentation about PA technology

Pozen strikes manufacturing pact with Patheon for heart drug

Pozen's new cardiovascular drug does not even have a name yet, but it has a manufacturer to produce it once it gets U.S. Food and Drug Administration approval.

Pozen's $75M deal - It's all about cash for product pipeline

The money strengthens Pozen's negotiating position as it seeks a partner for a drug under development and does so without diluting Pozen's shareholders, CEO John Platchetka

Pozen sells royalty rights to migraine drug for $75M

Treximet is marketed in the United States by Pozen drug partner GlaxoSmithKline. The royalty rights were purchased by a Canadian pension plan.

Pozen CEO criticizes partner AstraZeneca for slow drug sales

"Although last quarter's U.S. net sales were up from the second quarter, the $13.4 million year to date total is well below what we think Vimovo is capable of selling so AstraZeneca has work to be done to make that better," John Platchetka says.

Tech earnings: Pozen, DexOne, Biocryst, Furiex, Targacept

It's been a busy earnings week, and five North Carolina firms all reported losses.

Losers in Treximet patent decision are appealing

A securities filing by patent-holder Pozen says that generic drug-makers are appealing a ruling by a judge in that Pozen had exclusive rights to Treximet.

Pozen names exec for customer development

The Chapel Hill-based pharmaceutical firm looks to boost its own pipeline of products.

What a relief - Pozen prevails in patent fight

Pozen had sued the Par, Alphapharm and Dr. Reddy's claiming that those generic product infringe on its three migraine drug patents. The litigation was consolidated into one suit that was tried last October.

Pozen forms advisory board for thoughts on digital development

The Chapel Hill-based pharmaceutical firm is seeking advice about how to revolutionize drug industry marketing and development.

Semiconductor Research Corp., UCLA develop money-saving chip monitoring process; Pozen ranks high for efficiency; UNC's Thorp headlines medical device event

Pozen, AstraZeneca sue to block generic version of pain reliever